The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Xerostomia Market Research Report 2024
Synopsis
Drugs for Xerostomia include prescription and over-the-counter mouthwashes, artificial saliva or humectants to moisturize the mouth, mouthwashes specially for dry mouth, especially those containing xylitol
Global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for Xerostomia market research.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Segment by Application
Supermarket
Hospital
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Drugs for Xerostomia report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Drugs for Xerostomia include prescription and over-the-counter mouthwashes, artificial saliva or humectants to moisturize the mouth, mouthwashes specially for dry mouth, especially those containing xylitol
Global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for Xerostomia market research.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Segment by Application
Supermarket
Hospital
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Drugs for Xerostomia report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Drugs for Xerostomia Market Overview
1.1 Product Overview and Scope of Drugs for Xerostomia
1.2 Drugs for Xerostomia Segment by Type
1.2.1 Global Drugs for Xerostomia Market Value Comparison by Type (2023-2029)
1.2.2 Spray
1.2.3 Oral Liquid
1.2.4 Buccal Tablet
1.2.5 Mouth Wash
1.3 Drugs for Xerostomia Segment by Application
1.3.1 Global Drugs for Xerostomia Market Value by Application: (2023-2029)
1.3.2 Supermarket
1.3.3 Hospital
1.3.4 Other
1.4 Global Drugs for Xerostomia Market Size Estimates and Forecasts
1.4.1 Global Drugs for Xerostomia Revenue 2018-2029
1.4.2 Global Drugs for Xerostomia Sales 2018-2029
1.4.3 Global Drugs for Xerostomia Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Drugs for Xerostomia Market Competition by Manufacturers
2.1 Global Drugs for Xerostomia Sales Market Share by Manufacturers (2018-2023)
2.2 Global Drugs for Xerostomia Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Drugs for Xerostomia Average Price by Manufacturers (2018-2023)
2.4 Global Drugs for Xerostomia Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Drugs for Xerostomia, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Xerostomia, Product Type & Application
2.7 Drugs for Xerostomia Market Competitive Situation and Trends
2.7.1 Drugs for Xerostomia Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs for Xerostomia Players Market Share by Revenue
2.7.3 Global Drugs for Xerostomia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Xerostomia Retrospective Market Scenario by Region
3.1 Global Drugs for Xerostomia Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Drugs for Xerostomia Global Drugs for Xerostomia Sales by Region: 2018-2029
3.2.1 Global Drugs for Xerostomia Sales by Region: 2018-2023
3.2.2 Global Drugs for Xerostomia Sales by Region: 2024-2029
3.3 Global Drugs for Xerostomia Global Drugs for Xerostomia Revenue by Region: 2018-2029
3.3.1 Global Drugs for Xerostomia Revenue by Region: 2018-2023
3.3.2 Global Drugs for Xerostomia Revenue by Region: 2024-2029
3.4 North America Drugs for Xerostomia Market Facts & Figures by Country
3.4.1 North America Drugs for Xerostomia Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Drugs for Xerostomia Sales by Country (2018-2029)
3.4.3 North America Drugs for Xerostomia Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Xerostomia Market Facts & Figures by Country
3.5.1 Europe Drugs for Xerostomia Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Drugs for Xerostomia Sales by Country (2018-2029)
3.5.3 Europe Drugs for Xerostomia Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Xerostomia Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs for Xerostomia Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Drugs for Xerostomia Sales by Country (2018-2029)
3.6.3 Asia Pacific Drugs for Xerostomia Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Drugs for Xerostomia Market Facts & Figures by Country
3.7.1 Latin America Drugs for Xerostomia Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Drugs for Xerostomia Sales by Country (2018-2029)
3.7.3 Latin America Drugs for Xerostomia Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Xerostomia Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Xerostomia Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Drugs for Xerostomia Sales by Country (2018-2029)
3.8.3 Middle East and Africa Drugs for Xerostomia Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Xerostomia Sales by Type (2018-2029)
4.1.1 Global Drugs for Xerostomia Sales by Type (2018-2023)
4.1.2 Global Drugs for Xerostomia Sales by Type (2024-2029)
4.1.3 Global Drugs for Xerostomia Sales Market Share by Type (2018-2029)
4.2 Global Drugs for Xerostomia Revenue by Type (2018-2029)
4.2.1 Global Drugs for Xerostomia Revenue by Type (2018-2023)
4.2.2 Global Drugs for Xerostomia Revenue by Type (2024-2029)
4.2.3 Global Drugs for Xerostomia Revenue Market Share by Type (2018-2029)
4.3 Global Drugs for Xerostomia Price by Type (2018-2029)
5 Segment by Application
5.1 Global Drugs for Xerostomia Sales by Application (2018-2029)
5.1.1 Global Drugs for Xerostomia Sales by Application (2018-2023)
5.1.2 Global Drugs for Xerostomia Sales by Application (2024-2029)
5.1.3 Global Drugs for Xerostomia Sales Market Share by Application (2018-2029)
5.2 Global Drugs for Xerostomia Revenue by Application (2018-2029)
5.2.1 Global Drugs for Xerostomia Revenue by Application (2018-2023)
5.2.2 Global Drugs for Xerostomia Revenue by Application (2024-2029)
5.2.3 Global Drugs for Xerostomia Revenue Market Share by Application (2018-2029)
5.3 Global Drugs for Xerostomia Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Concordia
6.1.1 Concordia Corporation Information
6.1.2 Concordia Description and Business Overview
6.1.3 Concordia Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Concordia Drugs for Xerostomia Product Portfolio
6.1.5 Concordia Recent Developments/Updates
6.2 AMICI
6.2.1 AMICI Corporation Information
6.2.2 AMICI Description and Business Overview
6.2.3 AMICI Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AMICI Drugs for Xerostomia Product Portfolio
6.2.5 AMICI Recent Developments/Updates
6.3 Aurobindo Pharma Ltd
6.3.1 Aurobindo Pharma Ltd Corporation Information
6.3.2 Aurobindo Pharma Ltd Description and Business Overview
6.3.3 Aurobindo Pharma Ltd Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Aurobindo Pharma Ltd Drugs for Xerostomia Product Portfolio
6.3.5 Aurobindo Pharma Ltd Recent Developments/Updates
6.4 Impax Labs
6.4.1 Impax Labs Corporation Information
6.4.2 Impax Labs Description and Business Overview
6.4.3 Impax Labs Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Impax Labs Drugs for Xerostomia Product Portfolio
6.4.5 Impax Labs Recent Developments/Updates
6.5 Lannett Co Inc
6.5.1 Lannett Co Inc Corporation Information
6.5.2 Lannett Co Inc Description and Business Overview
6.5.3 Lannett Co Inc Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Lannett Co Inc Drugs for Xerostomia Product Portfolio
6.5.5 Lannett Co Inc Recent Developments/Updates
6.6 Padagis Us
6.6.1 Padagis Us Corporation Information
6.6.2 Padagis Us Description and Business Overview
6.6.3 Padagis Us Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Padagis Us Drugs for Xerostomia Product Portfolio
6.6.5 Padagis Us Recent Developments/Updates
6.7 Amneal Pharmaceuticals Pvt. Ltd.
6.6.1 Amneal Pharmaceuticals Pvt. Ltd. Corporation Information
6.6.2 Amneal Pharmaceuticals Pvt. Ltd. Description and Business Overview
6.6.3 Amneal Pharmaceuticals Pvt. Ltd. Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amneal Pharmaceuticals Pvt. Ltd. Drugs for Xerostomia Product Portfolio
6.7.5 Amneal Pharmaceuticals Pvt. Ltd. Recent Developments/Updates
6.8 Bausch Health Companies Inc.
6.8.1 Bausch Health Companies Inc. Corporation Information
6.8.2 Bausch Health Companies Inc. Description and Business Overview
6.8.3 Bausch Health Companies Inc. Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bausch Health Companies Inc. Drugs for Xerostomia Product Portfolio
6.8.5 Bausch Health Companies Inc. Recent Developments/Updates
6.9 GSK
6.9.1 GSK Corporation Information
6.9.2 GSK Description and Business Overview
6.9.3 GSK Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GSK Drugs for Xerostomia Product Portfolio
6.9.5 GSK Recent Developments/Updates
6.10 Jazz Pharmaceuticals plc
6.10.1 Jazz Pharmaceuticals plc Corporation Information
6.10.2 Jazz Pharmaceuticals plc Description and Business Overview
6.10.3 Jazz Pharmaceuticals plc Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Jazz Pharmaceuticals plc Drugs for Xerostomia Product Portfolio
6.10.5 Jazz Pharmaceuticals plc Recent Developments/Updates
6.11 Mission Pharmacal Company
6.11.1 Mission Pharmacal Company Corporation Information
6.11.2 Mission Pharmacal Company Drugs for Xerostomia Description and Business Overview
6.11.3 Mission Pharmacal Company Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mission Pharmacal Company Drugs for Xerostomia Product Portfolio
6.11.5 Mission Pharmacal Company Recent Developments/Updates
6.12 OraCoat
6.12.1 OraCoat Corporation Information
6.12.2 OraCoat Drugs for Xerostomia Description and Business Overview
6.12.3 OraCoat Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.12.4 OraCoat Drugs for Xerostomia Product Portfolio
6.12.5 OraCoat Recent Developments/Updates
6.13 Cumberland Pharmaceuticals, Inc.
6.13.1 Cumberland Pharmaceuticals, Inc. Corporation Information
6.13.2 Cumberland Pharmaceuticals, Inc. Drugs for Xerostomia Description and Business Overview
6.13.3 Cumberland Pharmaceuticals, Inc. Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Cumberland Pharmaceuticals, Inc. Drugs for Xerostomia Product Portfolio
6.13.5 Cumberland Pharmaceuticals, Inc. Recent Developments/Updates
6.14 Fleet, C.B., Company
6.14.1 Fleet, C.B., Company Corporation Information
6.14.2 Fleet, C.B., Company Drugs for Xerostomia Description and Business Overview
6.14.3 Fleet, C.B., Company Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Fleet, C.B., Company Drugs for Xerostomia Product Portfolio
6.14.5 Fleet, C.B., Company Recent Developments/Updates
6.15 Parnell Pharmaceuticals, Inc
6.15.1 Parnell Pharmaceuticals, Inc Corporation Information
6.15.2 Parnell Pharmaceuticals, Inc Drugs for Xerostomia Description and Business Overview
6.15.3 Parnell Pharmaceuticals, Inc Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Parnell Pharmaceuticals, Inc Drugs for Xerostomia Product Portfolio
6.15.5 Parnell Pharmaceuticals, Inc Recent Developments/Updates
6.16 Clinigen
6.16.1 Clinigen Corporation Information
6.16.2 Clinigen Drugs for Xerostomia Description and Business Overview
6.16.3 Clinigen Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Clinigen Drugs for Xerostomia Product Portfolio
6.16.5 Clinigen Recent Developments/Updates
6.17 Sun Pharm
6.17.1 Sun Pharm Corporation Information
6.17.2 Sun Pharm Drugs for Xerostomia Description and Business Overview
6.17.3 Sun Pharm Drugs for Xerostomia Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Sun Pharm Drugs for Xerostomia Product Portfolio
6.17.5 Sun Pharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Xerostomia Industry Chain Analysis
7.2 Drugs for Xerostomia Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Xerostomia Production Mode & Process
7.4 Drugs for Xerostomia Sales and Marketing
7.4.1 Drugs for Xerostomia Sales Channels
7.4.2 Drugs for Xerostomia Distributors
7.5 Drugs for Xerostomia Customers
8 Drugs for Xerostomia Market Dynamics
8.1 Drugs for Xerostomia Industry Trends
8.2 Drugs for Xerostomia Market Drivers
8.3 Drugs for Xerostomia Market Challenges
8.4 Drugs for Xerostomia Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
